Allakos (STU:37Z) Current Accrued Expense : €12.16 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Allakos Current Accrued Expense?

Allakos's Current Accrued Expense for the quarter that ended in Mar. 2024 was €12.16 Mil.

Allakos's quarterly Current Accrued Expense increased from Sep. 2023 (€11.30 Mil) to Dec. 2023 (€20.41 Mil) but then declined from Dec. 2023 (€20.41 Mil) to Mar. 2024 (€12.16 Mil).

Allakos's annual Current Accrued Expense declined from Dec. 2021 (€14.35 Mil) to Dec. 2022 (€13.17 Mil) but then increased from Dec. 2022 (€13.17 Mil) to Dec. 2023 (€20.41 Mil).

Allakos Current Accrued Expense Historical Data

The historical data trend for Allakos's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Current Accrued Expense Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

4.49

3.86

14.35

13.17

20.41

Allakos Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															11.60	11.07	11.30	20.41	12.16

Allakos Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Allakos Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Allakos's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (STU:37Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALLK:USA

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (STU:37Z) Headlines

No Headlines